Non-invasive prenatal diagnosis of the most common aneuploidies with cell-free fetal DNA in maternal serum-preliminary results;Nieinwazyjna diagnostyka prenatalna najcze{ogonek}stszych aneuploidii na podstawie płodowego DNA we krwi matki-doniesienie wste{ogonek}pne

Ginekologia Polska

Volumn 85, Issue 3, 2014, Pages 208-213

  Bijok, Julia ^a,c   Gorzelnik, Katarzyna ^a   Massalska, Diana ^a   Ilnicka, Alicja ^b   Pawłowska, Barbara ^b   Zimowski, Janusz G ^b   Kucińska Chahwan, Anna ^a,b   Jakiel, Grzegorz ^a,c   Roszkowski, Tomasz ^a,c  

^a SPSK im Prof Orłowskiego ^*  (Poland)

^b INSTITUTE OF PSYCHIATRY AND NEUROLOGY   (Poland)

^c MEDICAL CENTER FOR POSTGRADUATE EDUCATION   (Poland)

Author keywords

Chromosomal aberrations; Nell free fetal DNA NffDNA; Non invasive fetal trisomy test NIFTY; Non invasive prenatal diagnosis NIPD

Indexed keywords

DNA;

ADULT; ANEUPLOIDY; ARTICLE; BLOOD; CELL FREE SYSTEM; CHEMISTRY; CHROMOSOME 13; CHROMOSOME 18; CHROMOSOME 21; CHROMOSOME ABERRATION; CHROMOSOME DISORDER; COMPARATIVE STUDY; FEMALE; FETUS BLOOD; HUMAN; KARYOTYPING; MATERNAL SERUM SCREENING TEST; METHODOLOGY; MOSAICISM; PHYSIOLOGY; PREGNANCY; PRENATAL DEVELOPMENT; PRENATAL DIAGNOSIS; SERUM; TRISOMY; TRISOMY 18;

ADULT; ANEUPLOIDY; CELL-FREE SYSTEM; CHROMOSOME ABERRATIONS; CHROMOSOME DISORDERS; CHROMOSOMES, HUMAN, PAIR 13; CHROMOSOMES, HUMAN, PAIR 18; CHROMOSOMES, HUMAN, PAIR 21; DNA; FEMALE; FETAL BLOOD; HUMANS; KARYOTYPING; MATERNAL SERUM SCREENING TESTS; MOSAICISM; PREGNANCY; PRENATAL DIAGNOSIS; SERUM; TRISOMY;

EID: 84900445318     PISSN: 00170011     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. Ghaffari SR, Tahmasebpour AR, Jamal A, [et al.]. First-trimester screening for chromosomal abnormalities by integrated application of nuchal translucency, nasal bone, tricuspid regurgitation and ductus venosus flow combined with maternal serum free -hCG and PAPP-A: a 5-year prospective study. Ultrasound Obstet Gynecol. 2012, 39 (5), 528-534.
2. Kagan KO, Wright D, Baker A, [et al.]. Screening for trisomy 21 by maternal age, fetal nuchal translucency thickness, free beta-human chorionic gonadotropin and pregnancy-associated plasma protein-A. Ultrasound Obstet Gynecol. 2008, 31 (6), 618-624.
3. Nicolaides KH, Spencer K, Avgidou K, [et al.]. Multicenter study of first-trimester screening for trisomy 21 in 75 821 pregnancies: results and estimation of the potential impact of individual risk-orientated two-stage first-trimester screening. Ultrasound Obstet Gynecol. 2005, 25 (3), 221-226.
4. Nicolaides KH. Screening for fetal aneuploidies at 11 to 13 weeks. Prenat Diagn. 2011, 31 (1), 7-15.
5. Tabor A, Alfirevic Z. Update on procedure-related risks for prenatal diagnosis techniques. Fetal Diagn Ther. 2010, 27 (1), 1-7.
6. Tabor A, Vestergaard CH, Lidegaard ø. Fetal loss rate after chorionic villus sampling and amniocentesis: an 11-year national registry study. Ultrasound Obstet Gynecol. 2009, 34 (1), 19-24.
7. Walknowska J, Conte FA, Grumbach MM. Practical and theoretical implications of fetal-maternal lymphocyte transfer. Lancet. 1969,1 (7606), 1119-1122.
8. Lo YM, Corbetta N, Chamberlain PF, [et al.]. Presence of fetal DNA in maternal plasma and serum. Lancet. 1997, 350 (9076), 485-487.
9. Lo YM, Tein MS, Lau TK, [et al.]. Quantitative analysis of fetal DNA in maternal plasma and serum: implications for noninvasive prenatal diagnosis. Am J Hum Genet. 1998, 62 (4), 768-775.
10. Zhu YJ, Zheng YR, Li L, [et al.]. Diagnostic accuracy of non-invasive fetal RhD genotyping using cell-free fetal DNA: a meta analysis. J Matern Fetal Neonatal Med. 2014,Feb 10.
11. Lo YM, Chiu RW. Noninvasive prenatal diagnosis of fetal chromosomal aneuploidies by maternal plasma nucleic acid analysis. Clin Chem. 2008, 54 (3), 461-466.
12. Moorthie S, Mattocks CJ, Wright CF. Review of massively parallel DNA sequencing technologies. Hugo J. 2011, 5(1-4), 1-12.
13. Jiang F, Ren J, Chen F, [et al.]. Noninvasive Fetal Trisomy (NIFTY) test: an advanced noninvasive prenatal diagnosis methodology for fetal autosomal and sex chromosomal aneuploidies. BMC Med Genomics. 2012, 5 (1), 57.
14. Gorzelnik K, Bijok J, Zimowski J, [et al.]. Nieinwazyjna diagnostyka prenatalna trisomii 21, 18 i 13 z wykorzystaniem wolnego pozakomórkowego DNA plodu. Ginekol Pol. 2013, 84 (08), 714-719.
15. Chiu RWK, Chan KCA, Gao Y, [et al.]. Noninvasive prenatal diagnosis of fetal chromosomal aneuploidy by massively parallel genomic sequencing of DNA in maternal plasma. Proc Natl Acad Sci U S A. 2008, 105 (51), 20458-20463.
16. Liang D, Lv W, Wang H, [et al.]. Non-invasive prenatal testing of fetal whole chromosome aneuploidy by massively parallel sequencing. Prenat Diagn. 2013, 33 (5), 409-415.
17. Chiu RW, Akolekar R, Zheng YW, [et al.]. Non-invasive prenatal assessment of trisomy 21 by multiplexed maternal plasma DNA sequencing: large scale validity study. BMJ. 2011, 342, c7401.
18. Devers PL, Cronister A, Ormond KE, [et al.]. Noninvasive prenatal testing/noninvasive prenatal diagnosis: the position of the national society of genetic counselors. J Genet Couns. 2013, 22 (3), 291-295.
19. Garfield SS, Armstrong SO. Clinical and cost consequences of incorporating a novel noninvasvie prenatal test into the diagnostic pathway for fetal trisomies. J Managed Care Med. 2012, 15, 34-41.
20. Hui L. Non-invasive prenatal testing for fetal aneuploidy: charting the course from clinical validity to clinical utility. Ultrasound Obstet Gynecol. 2013, 41 (1), 2-6.
21. Silver RK, Blum K, Geibel LJ, [et al.]. Clinical implications of atypical chromosome abnormalities diagnosed prenatally. Obstet Gynecol. 1999, 94 (6), 925-928.
22. Bijok J, Szyszka M, Michalowska A, [et al.]. Analiza biopsji trofoblastu przeprowadzonych w I Klinice Ginekologii i Poloznictwa-CMKP SPSK im. Prof. Orlowskiego w Warszawie-doniesienie wstepne. Perinatologia, Neonatologia i Ginekologia. 2010, 3 (2), 145-152.
23. Palomaki GE, Kloza EM, Lambert-Messerlian GM, [et al.]. DNA sequencing of maternal plasma to detect Down syndrome: an international clinical validation study. Genet Med. 2011, 13 (11), 913-920.
24. Ashoor G, Syngelaki A, Poon LC, [et al.]. Fetal fraction in maternal plasma cell-free DNA at 11-13 weeks' gestation: relation to maternal and fetal characteristics. Ultrasound Obstet Gynecol. 2013, 41 (1), 26-32.
25. Haghiac M, Vora NL, Basu S, [et al.]. Increased death of adipose cells, a path to release cell-free DNA into systemic circulation of obese women. Obesity (Silver Spring). 2012, 20 (11), 2213-2219.
26. Ashoor G, Poon L, Syngelaki A, [et al.]. Fetal fraction in maternal plasma cell-free DNA at 11-13weeks' gestation: effect of maternal and fetal factors. Fetal Diagn Ther. 2012, 31 (4), 237-243.
27. Barrett AN, Zimmermann BG, Wang D, [et al.]. Implementing prenatal diagnosis based on cellfree fetal DNA: accurate identification of factors affecting fetal DNA yield. PLoS One. 2011, 6 (10), e25202.
28. Hidestrand M, Stokowski R, Song K, [et al.]. Influence of temperature during transportation on cell-free DNA analysis. Fetal Diagn Ther. 2012, 31 (2), 122-128.
29. Nicolaides KH, Syngelaki A, Ashoor G, [et al.]. Noninvasive prenatal testing for fetal trisomies in a routinely screened first-trimester population. Am J Obstet Gynecol. 2012, 207 (5), 374.e1-6.
30. Akolekar R, Syngelaki A, Poon L, [et al.]. Competing risks model in early screening for preeclampsia by biophysical and biochemical markers. Fetal Diagn Ther. 2013, 33 (1), 8-15.